Compositions and methods for identifying and targeting cancer cells of alimentary canal origin

• US 7,479,376 B2
• Filed: 01/14/2005
• Issued: 01/20/2009
• Est. Priority Date: 03/27/2000
• Status: Expired due to Fees

• Current Assignee: Thomas Jefferson University (Main Line Health System)
• Original Assignee: Thomas Jefferson University (Main Line Health System)
• Inventors: Waldman, Scott A., Park, Jason, Schulz, Stephanie
• Primary Examiner(s): Yu; Misook
• Application Number:
  US11/036,875
• Publication Number:
  US 20050164267A1
• Time in Patent Office: 1,467 Days
• Field of Search: None
• US Class Current: 435/7.23
• CPC Class Codes: A61K 31/7034 attached to a carbocyclic compound, e.g. phloridzin
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 39/001102 Receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: A61K 47/6871 the antibody targeting an enzyme
• CPC Class Codes: A61K 51/1075 the antibody being against an enzyme
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/3046 Stomach, Intestines
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2333/988 Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
• CPC Class Codes: G01N 33/57407 Specifically defined cancers
• CPC Class Codes: G01N 33/57419 of colon
• CPC Class Codes: G01N 33/57446 of stomach or intestine

Abstract

Screening and diagnostic reagents, kits and methods for metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed.

Claims

1. An in vitro method of screening an individual for metastatic colorectal cancer cells or primary and/or metastatic stomach or esophageal cancer cells comprising the steps of examining a sample of extraintestinal tissue and/or body fluids from an individual to detect the presence of CDX2 protein in cells in said sample wherein the presence of CDX2 protein indicates a possibility of metastatic colorectal cancer cells or primary and/or metastatic stomach or esophageal cancer cells in said sample.

2. The method of claim 1 wherein CDX2 protein is detected by immunoassay wherein said sample is contacted with antibodies that specifically bind to CDX2 gene translation product.

19. The method of claim 1 wherein said sample is blood.

20. The method of claim 1 wherein said sample is a lymph node sample.

25. The method of claim 1 wherein said sample is a sample of extraintestinal tissue.

26. The method of claim 25 wherein CDX2 protein is detected by immunoassay wherein said sample is contacted with antibodies that specifically bind to CDX2 gene translation product.

3. An in vitro method of detecting metastatic colorectal cancer in an individual diagnosed with primary colorectal cancer comprising the steps of examining a sample of extraintestinal tissue and/or body fluids from said individual to detect the presence of CDX2 protein in said sample wherein the presence of CDX2 protein in said sample indicates that the individual has metastatic colorectal cancer.

4. The method of claim 3 wherein the presence of CDX2 protein is detected by immunoassay wherein said sample is contacted with antibodies that specifically bind to CDX2 protein.

21. The method of claim 3 wherein said sample is blood.

22. The method of claim 3 wherein said sample is a lymph node sample.

27. The method of claim 3 wherein said sample is a sample of extraintestinal tissue.

28. The method of claim 27 wherein CDX2 protein is detected by immunoassay wherein said sample is contacted with antibodies that specifically bind to CDX2 gene translation product.

5. An in vitro method of confirming that a tumor cell removed from a patient suspected of having colorectal, stomach or esophageal cancer cells is a colorectal, stomach or esophageal tumor cell comprising the step of detecting the presence of CDX2 protein in a tumor cell wherein the presence of CDX2 protein indicates that the tumor cell is a colorectal, stomach or esophageal tumor cell.

6. The method of claim 5 wherein the presence of CDX2 by said tumor cell is detected by immunoassay wherein protein from said tumor cell is contacted with antibodies that specifically bind to CDX2 protein.

23. The method of claim 5 wherein said tumor cell is removed from a patient suspected of having esophageal cancer.

24. The method of claim 5 wherein said tumor cell is removed from a patient suspected of having stomach cancer.

7. A method of diagnosing metastatic esophageal cancer in an individual who has been diagnosed with primary esophageal cancer comprising the step of examining a sample of extraintestinal tissue and/or body fluids from an individual to detect the presence of CDX2 protein in the sample, wherein the presence of CDX2 protein indicates that the individual has metastatic esophageal cancer.

8. The method of claim 7 wherein CDX2 protein is detected by immunoassay wherein the sample is contacted with antibodies that specifically bind to CDX2 protein.

9. The method of claim 7 wherein said sample is body fluid.

10. The method of claim 7 wherein said sample is blood.

11. The method of claim 7 wherein said sample is lymphatic tissue and/or fluid.

12. The method of claim 7 wherein said sample is a lymph node sample.

29. The method of claim 7 wherein said sample is a sample of extraintestinal tissue.

30. The method of claim 29 wherein CDX2 protein is detected by immunoassay wherein said sample is contacted with antibodies that specifically bind to CDX2 gene translation product.

13. A method of diagnosing metastatic stomach cancer in an individual who has been diagnosed with primary stomach cancer comprising the steps of examining a sample of extraintestinal tissue and/or body fluids from an individual to detect the presence of CDX2 protein in said sample wherein the presence of CDX2 protein indicates that the individual has metastatic stomach cancer.

14. The method of claim 13 wherein CDX2 protein is detected by immunoassay wherein said sample is contacted with antibodies that specifically bind to CDX2 protein.

15. The method of claim 13 wherein said sample is body fluid.

16. The method of claim 13 wherein said sample is blood.

17. The method of claim 13 wherein said sample is lymphatic tissue and/or fluid.

18. The method of claim 13 wherein said sample is a lymph node sample.

31. The method of claim 13 wherein said sample is a sample of extraintestinal tissue.

32. The method of claim 31 wherein CDX2 protein is detected by immunoassay wherein said sample is contacted with antibodies that specifically bind to CDX2 gene translation product.